Meetings

Insilico Medicine announced it will present three abstracts at the 2026 Crohn’s & Colitis Congress in Las Vegas on January 23, 2026, featuring new data supporting the continued development of ISM5411 (ISM012-042), an orally administered, gut-restricted small-molecule inhibitor of PHD1/2 for inflammatory bowel disease. ISM5411 is designed to stabilize HIF-1α locally in the gastrointestinal tract to promote protective mucosal gene expression, support intestinal barrier repair, and reduce inflammation while limiting systemic exposure.

The presentations include first-in-human Phase 1 results in healthy volunteers showing favorable safety, tolerability, and pharmacokinetics consistent with gut restriction; 13-week repeat-dose toxicology studies in rats and dogs demonstrating good tolerability and a NOAEL at the highest dose tested; and preclinical efficacy in a chronic T cell transfer-induced colitis model, where ISM5411 reduced disease severity in both preventive and therapeutic settings, including in combination with anti-TNF therapy. Together, the data reinforce ISM5411’s potential as a novel approach to IBD that supports mucosal healing by strengthening epithelial integrity while regulating inflammatory pathways.

On 24 October 2025 at SBSTTA-27 in Panama City, CO-OP4CBD together with Biodiversa+ co-hosted a side event highlighting the vital role of knowledge holders in strengthening the science–policy interface for the implementation of the Kunming-Montreal Global Biodiversity Framework. The session showcased capacity-building initiatives and presented a preview of a jointly developed UN CBD Guide.